Biomedical subjects

L Faltýnek

Publications and source records attributed to L Faltýnek.

At least 19 recordsLinked to original sources

PubMed1998

[The importance of determination of interleukin-10 in the blood of patients with systemic lupus erythematosus].

BACKGROUND: Hitherto, not very numerous investigations provided so far only few often controversial findings on the importance of interleukin-10 (IL-10) in systemic lupus erythematosus (SLE). The objective of the present investigation was to assess whether there exist practically applicable relations between the serum level of IL-10, clinical and laboratory indicators of activity of the disease and serum levels of selected cytokines or their soluble receptors. METHODS AND RESULTS: The authors analyzed a group of 23 patients with SLE (23 women and 1 man, median age 37 years). Interleukin-10 and other cytokines were examined by the ELISA method, the clinical activity of the disease was evaluated by the ECLAM system (European Consensus Lupus Activity Measurement). Elevated IL-10 values (> 5 pg/ml) were assessed in 10 (43%) patients. Correlation analysis (Pearson's test, p < 0.05) revealed statistically significant relations between IL-10 levels and the activity of the disease, values of antibody levels against dsDNA and levels of the soluble receptor IL-2 (sIL-2R) in serum. Conversely, no relationship was revealed between values of IL-10 and values of C3 and C4 complement components, IL-1, IL-2, IL-6, sIL-6R, TNF-alpha, sTNFR-alpha and INF-gamma. CONCLUSIONS: Elevated IL-10 serum levels in patients with SLE did not have, with the exception of the index of clinical activity of the disease, antibodies against dsDNA and sIL-2R any statistically significant relations to laboratory indicators of disease activity and levels of selected cytokines and their soluble receptors.

Adolescent↗

PubMed1995

[Serum interleukin-6 in multiple myeloma: I. Relation to selected laboratory indicators of disease].

In a group of 111 patients with multiple myeloma (MM) comprising a group of 34 patients examined when the diagnosis was established and a group of 77 patients evaluated in different stages of the disease, the author examined the relationship between the interleukin-6 serum level (IL-6), assessed by the method of enzyme immunoanalysis and selected laboratory indicators of the disease. Elevated IL-6 values were recorded in 38% of the patients. In neither of the groups significant relations were found between IL-6 and calcium, urea, creatinine levels, the amount and type of monoclonal immunoglobulin, lacticode dehydrogenase, beta 2-microglobulin, ferritin, IL-2 and its soluble receptor in serum and the incidence of myeloma plasmocytes in bone marrow. In the second (but not in the first) group a significant relationship was recorded between IL-6 levels and the red cell sedimentation rate, the Hb value, the CRP level and serum albumin and the value of thymidinekinase in serum of patients with a value beyond the normal range. From the investigation ensues that examination of IL-6 serum levels in MM contributes so far mainly to improvement of the diagnosis and expedient classification of this disease in clinical practice.

Adult↗

PubMed1994

[Clinical importance of the paraprotein index in multiple myeloma].

In a group of 54 patients with multiple myeloma, hitherto not treated by chemotherapy, the paraprotein index was assessed. It was revealed that this simple and readily available indicator is related to the degree of anaemia, the serum beta-2-microglobulin value, the degree of bone marrow infiltration by myeloma plasmocytes and the survival period. The authors found no relation to age, albumin, urea, creatinine, serum calcium values and degree of skeletal affection. It was revealed that values of the paraprotein index declined with the advancing disease evaluated according to Durie-Salmon's system. It may be said that the paraprotein index can be considered in patients with multiple myeloma an indicator which contributes to more profound knowledge of individual biological characteristics of the myeloma population and the prognosis of the disease.

Female↗

PubMed1993

[Treatment of resistant forms of multiple myeloma using a combination of mitoxantrone, vincristine and prednisone (the NOP regimen)].

In the submitted study the authors summarize experience with the treatment of resistant forms of multiple myeloma by a combination of Mitoxantrone, Vincristine and Prednisone (NOP regime). The above treatment produced an objective therapeutic response in 33% of the patients, in 50% a partial response, in 17% it failed. The median of survival in the whole group was 10.5 months. Substantially poorer therapeutic results were recorded in patients with primary resistance to the initial chemotherapy (objective response only in one of 6 patients) than in the group with secondary resistance which developed during a relapse of the disease (objective response in 3 of 6 patients). With the exception of marked leukopenia and neutropenia treatment by the NOP regime was very well tolerated. The NOP regime is an expedient approach which extends practical possibilities, in particular ambulatory treatment of refractory forms of multiple myeloma.

Adult↗

PubMed1986